Realizing Promise of
Novel, Dynamically
Re-Thinking the Role of Immunomodulators: Dynamic Dual Action READ MORE » Seeking Balance
in COVID-19
Immune Storms

LATEST NEWS: September 6, 2023

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

logo logo
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil.

Shalom Z. Hirschman, MD, Chief Medical Officer of EOM Pharmaceuticals, stated: “I am encouraged by the results of this trial indicating that EOM613 was well-tolerated even in this group of seriously affected hospitalized COVID-19 patients, as it had earlier been shown to be trials in patients with AIDS, cancer cachexia and rheumatoid arthritis. Furthermore, I am pleased that the serum cytokine measurements in COVID-19 patients validate the putative mechanism of action of EOM613 as a broad-spectrum immunomodulating agent affecting pro- and anti-inflammatory cytokine levels, as these results are consistent with previous results in cell culture in immune cells. Both sIL-2R and IL-10 cytokines have been implicated in the scientific literature as biomarkers for the progression of severe COVID-19 infection, with elevated levels of sIL-2R in particular being a predictor of hospital mortality. Thus, an agent that can be shown to diminish serum levels of this cytokine may prove beneficial. Cytokines such as sIL-2R are also associated in various other chronic inflammatory conditions such as rheumatoid arthritis in which enhanced T-cell activation is involved.”


Our Mission

To rescue, repair, and restore health in patients suffering
from debilitating and sometimes deadly diseases

Our Values

Power science
Strive relentlessly
Support each other and humankind

Read More »

Rescue, Repair, and Restore

EOM Pharmaceuticals’ goal is to rescue, repair, and restore health. We are focused on developing novel drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases.

Rethinking the Role of Immunomodulators
Watch how EOM Pharmaceuticals is rethinking the role of immunomodulators with its novel, dynamically dual-acting, broad-spectrum lead asset, EOM613, which can produce anti- and pro-inflammatory effects and could mitigate a hyperimmune reaction or “cytokine storm.”

Our Pipeline


An investigational, novel, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and is believed to have both anti-inflammatory and pro-inflammatory broad-spectrum cytokine effects. In human cell culture studies, EOM613 demonstrated a unique “dynamic dual action” by suppressing or stimulating monocytes and macrophages depending on the activation state and environment of those key immune cells.1,2,3 It is hypothesized that this dynamic dual action may overcome a limitation of many approved immunomodulators that only reduce the inflammatory state, without achieving immune system balance.


An investigational, broad-spectrum aminosterol with a unique intracellular mechanism for the treatment of retinal diseases. EOM147 is believed to affect multiple angiogenic growth factors such as VEGF, PdGF, and bFGF. This mechanism of action is uniquely differentiated from other retinal therapies that are only anti-VEGF and administered as an intraocular injection. The novel formulation, administererd as an eye drop, represents a potential breakthrough that does not require intraocular injection.

EOM147 is being developed as proprietary, newly reformulated eye drop, containing a steroid-polyamine conjugate compound with broad-spectrum antimicrobial activity and anti-angiogenic activity.

News Highlights